Protalix BioTherapeutics Announces First Quarter 2024 Financial and Business Results on May 10, 2024

Company that organizes conference calls and webcasts

8:30am EDT

CARMIEL,

Israel

,

May 3, 2024

/PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, manufacturing and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx

^®

plant cell-based protein expression system today announced that it will report its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.

Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference call details:

Date:

Friday May 10, 2024

Time:

8:30 AM Eastern Daylight Time (EDT)

Toll-free:

1-877-423-9813

International:

1-201-689-8573

Israeli Free:

1 809 406 247

Conference ID:

13745800

Call Me™:

https://tinyurl.com/4pkhcxcj

The Call me™ feature allows you to avoid waiting for an operator; you enter your phone number into the platform and the system will call you immediately.

Webcast details:

Company link: https://protalixbiotherapeutics.gcs-web.com/events0

Webcast link: https://tinyurl.com/3r8rks24

Conference ID: 13745800

Participants are requested to access the call at least 15 minutes before the conference to register, download and install the necessary audio software. A replay of the call will be available for two weeks on the events calendar of the investor section of the company’s website, via the link above.

About Protalix BioTherapeutics, Inc.

Protalix is ​​a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to receive U.S. Food and Drug Administration (FDA) approval for a protein produced via a plant cell-based suspension expression system. This unique expression system represents a new method for developing recombinant proteins on an industrial scale. Protalix has acquired Pfizer Inc. licensed the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix’s first product manufactured through ProCellEx, excluding

Brazil

, where Protalix retains full rights. Protalix’s second product, Elfabrio

^®

was approved in by both the FDA and the European Medicines Agency

May 2023

.

Protalix collaborates with Chiesi Farmaceutici SpA for the global development and commercialization of Elfabrio. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a long-acting plant cell-expressed DNase I for the treatment of NETs-related diseases; and others.

Logo – https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

Contact person for investors

Mike Moyer

Director

LifeSci Advisors

+1-617-308-4306

[email protected]

View original content: https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2024-financial-and-business-results-on-may-10-2024-302134924. html

SOURCE Protalix BioTherapeutics, Inc.